- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05717036
Refractix DSP and TS Meter-DSP Measurement Comparison
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The TS Meter-DSP and investigational Refractix DSP are digital refractometers intended for the quantitative measurement of total protein in human serum or plasma. The devices are intended for use in plasma collection centers and are not for diagnostic purposes. Serum/plasma samples are taken from a successful microhematocrit assay and dispensed via pipette on to the instruments. The instruments measure the temperature compensated refractive index of the serum or plasma sample and digitally convert refractive index to an accurate total protein value. Potential donors with a total protein level of between 6.0 g/100ml and 9.0 g/100ml and that meet other pre-screening requirements are permitted to donate plasma.
These devices are FDA Class I in vitro diagnostic devices; FDA Regulation Number 862.2800 Refractometer for clinical use; with Product Code PSM, Refractometer for Donor Testing.
Participants will be those presenting for plasma donation. Ordinary pre-screening for plasma donation includes a fingerstick and the collection of one small capillary tube (<0.085ml) of blood. Participants who have consented to this study will be asked to supply a second capillary tube (<0.085ml) of blood for the clinical trial. The two samples will be centrifuged and hematocrit measured per the plasma center's standard operating procedures. One sample will be dispensed onto the TS Meter-DSP for total protein measurement. This measurement will be used to determine the individual's eligibility to donate plasma. The second sample will be dispensed on to the investigational Refractix DSP for total protein measurement. The measurements from both devices will be recorded on the Case Report Form. The study requires (36) participants with total protein measurements between 6.0 g/100ml and 9.0 g/100ml.
The primary analysis of data will include:
- a Grubb's test for outlying paired difference values will be performed. If outliers are detected and a plausible non-device failure mechanism can be identified (eg, operator or data entry error), the values will be excluded from the acceptance criterion calculations;
- an alpha=0.05 level equivalence test with an equivalence interval of +/- 0.3 g/100ml will be performed using the TOST (Two One Sample Test) procedure. A paired t-test 90% confidence interval for the difference in paired sample measurements will be constructed and reported; and
- calculate the percentage of measurement pairs falling outside of the +/-0.3 tolerance.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Linton Davis
- Phone Number: 754-336-1503
- Email: ldavis@hemarus-plasma.com
Study Contact Backup
- Name: Melvyn W Kramer, MD
- Phone Number: 978-333-1997
- Email: melvynkramer@aol.com
Study Locations
-
-
Florida
-
Lauderhill, Florida, United States, 33313
- Hemarus Plasma
-
Contact:
- Linton W Davis
- Phone Number: 754-336-1503
- Email: ldavis@hemarus-plasma.com
-
Contact:
- Melvyn W Kramer, MD
- Phone Number: 9783331997
- Email: melvynkramer@aol.com
-
Principal Investigator:
- Melvyn W Kramer, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects must be between the ages of 18 and 90 years old
- Subjects must be able and willing to provide signed informed consent
- Subjects must be able to follow study instructions
Exclusion Criteria:
- Insufficient amount of plasma sample for use on either device in the study.
- Plasma samples of with total protein measurements outside of the 6.0 g/100ml to 9.0 g/100ml range will be excluded from the data analysis.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
TS Meter-DSP Measurement and Refractix DSP Measurement
The study will involve blood serum samples from (36) participants.
Participants will be those presenting at a plasma collection center for routine plasma donation.
Ordinary pre-screening for plasma donation includes a fingerstick and the collection of one small capillary tube (<0.085ml) of blood.
Participants will be asked to provide a second capillary tube (<0.085ml) of blood from this fingerstick.
|
The two blood samples will be centrifuged and hematocrit measured per the plasma center's standard operating procedures.
One participant sample will be dispensed onto the cleared TS Meter-DSP for a serum total protein measurement.
This measurement will be used, along with other pre-screening information, to determine if the participant can donate plasma.
The second participant sample will be dispensed onto the investigational Refractix DSP for a serum total protein measurement.
It will be compared to the sample measurement taken on the cleared TS Meter-DSP.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Total Protein Measurement Comparison
Time Frame: Samples will be collected over one or two days at the plasma center. Data analysis by sponsor will be completed within 8 weeks.
|
The purpose of this study is to show the investigational Refractix DSP refractometer yields equivalent measurement results to the predicate device TS Meter-DSP through comparison testing using human plasma samples.
|
Samples will be collected over one or two days at the plasma center. Data analysis by sponsor will be completed within 8 weeks.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 13910000-TPR-30
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Serum Total Protein Measurement with TS Meter-DSP and Refractix DSP
-
Jagiellonian UniversityRecruiting